FAST NEWS: Henlius expects first-ever annual profit on strong drug sales
The latest: Shanghai Henlius Biotech Inc. (2696.HK) said on Monday it expects to report a net profit of 500 million yuan ($69.5 million) or more for 2023, reversing a loss of 695 million…
FAST NEWS: Henlius swings to the black on strong sales growth
The latest: Shanghai Henlius Biotech Inc. (2696.HK) on Wednesday reported a net profit of 408 million yuan ($56.2 million) in the first three quarters of this year, reversing a loss of…
FAST NEWS: Henlius Biotech’s revenue doubles in first quarter
The latest: Shanghai Henlius Biotech Inc. (2696.HK) reported its revenue soared 97.2% to 996 million yuan ($145 million) in the first quarter, according to a business update released on Sunday.…
RELATED ARTICLES
-
Shunned by investors, Henlius hangs up on its Hong Kong listing
2696.HK -
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
- CHINA BULLETIN: Manufacturing Déjà Vu
- CHINA BULLETIN: Factories Send Mixed Signals
- CHINA BULLETIN: Services, Trade Send Positive Signals
